Tandem Diabetes (TNDM) Tops Q4 EPS by 7c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Tandem Diabetes Care (TNDM) PT Raised to $4 at Stifel
March 5, 2018 7:16 AM ESTStifel raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $4.00 (from $3.00) while maintaining a Hold rating following the company's 4Q. sales were at the high end of the companys January 9th pre-announced $39-$40M range, and the company exited 2017 with record... More
Tandem Diabetes Care (TNDM) PT Doubled to $5 at Cowen; Outlook Improved Significantly
February 27, 2018 9:39 AM ESTCowen raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $5.00 (from $2.50) while maintaining a Market Perform rating.
Analyst Doug Schenkel commented, "The outlook has significantly improved. For the first time since we began covering TNDM, we believe there is a... More
Oppenheimer Starts Tandem (TNDM) at Outperform
February 27, 2018 8:14 AM ESTOppenheimer initiates coverage on Tandem (NASDAQ: TNDM) with a Outperform rating and a price target of $5.50.
For an analyst ratings summary and ratings history on Tandem click here. For more ratings news on Tandem click here.
Shares of Tandem closed at $3.10 yesterday.
... More